Illustration: Lazaro Gamio/Axios

ORIC Pharmaceuticals, a developer of therapies for treatment-resistant cancers, raised $120 million in its IPO. The San Francisco-based company priced 7.5 million shares at $16, versus initial plans to sell 5 million shares at between $14-$16, giving it an initial market cap of $441 million.

Why it matters: This reflects how the IPO market remains open for biotech startups and SPACs, likely because neither type of issuer has any revenue to lose from pandemic closures.

  • ROI: ORIC had raised $173 million in VC funding from firms like The Column Group (22.4% pre-IPO stake), Topspin Fund (15.6%), OrbiMed (11.7%), and EcoR1 Capital (5.8%).

The bottom line: "The discovery of ORIC’s lead experimental drug stemmed from work done by co-founder Charles Sawyers. Previously Sawyers was involved in the discovery of enzalutamide, which aims seeks to slow tumor cell growth by blocking androgens from binding with the androgen receptor. (Androgens, male sex hormones, prompt prostate cancer cell growth.) Another company co-founder, Scott Lowe, is a colleague of Sawyers and an expert in tumor networks and the factors in cancer cells’ response to treatment." — Sarah de Crescenzo, Xconomy

Go deeper: Meet the startups that have raised more than $1 billion

Go deeper

The hard seltzer wars are heating up

Illustration: Aïda Amer/Axios

Competition in the hard seltzer market is heating up in the closing weeks of summer, as big companies like Constellation Brands, AB InBev and Molson Coors have entered the market and Coca-Cola is poised to join the fray in 2021.

Why it matters: The coronavirus pandemic has increased alcohol sales overall and hard seltzers are exploding in popularity and look to have staying power, boasting record high sales in recent weeks.

Why you should be skeptical of Russia's coronavirus vaccine claims

Photo: Alexey Druzhini/Sputnik/AFP via Getty Images

Russian President Vladimir Putin announced Tuesday that his country has registered a coronavirus vaccine and said that one of his daughters has already been inoculated, AP reports.

Why it matters: Scientists around the world are skeptical about Russia's claims. There is no published scientific data to back up Putin's claims that Russia has a viable vaccine — or that it produces any sort of immunity without significant side effects.

A quandary for state unemployment agencies

Illustration: Aïda Amer/Axios

State agencies charged with paying unemployment benefits to jobless residents have their backs against the wall as they rush to parse President Trump's executive actions on coronavirus aid.

Why it matters: States are being asked to pitch in $100 per unemployed resident, but it’s a heavy lift for cash-strapped states that are still unclear about the details and may not opt-in at all. It leaves the states and jobless residents in a state of limbo.